NasdaqGS:MRSN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Mersana Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRSN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.7%

MRSN

-1.0%

US Biotechs

-3.1%

US Market


1 Year Return

1,197.6%

MRSN

31.3%

US Biotechs

12.7%

US Market

Return vs Industry: MRSN exceeded the US Biotechs industry which returned 31.2% over the past year.

Return vs Market: MRSN exceeded the US Market which returned 12.8% over the past year.


Shareholder returns

MRSNIndustryMarket
7 Day-8.7%-1.0%-3.1%
30 Day25.6%-0.5%-2.9%
90 Day3.5%-2.2%8.2%
1 Year1,197.6%1,197.6%33.6%31.3%15.3%12.7%
3 Year24.2%24.2%17.6%11.9%37.8%28.5%
5 Yearn/a27.2%18.2%90.9%69.4%

Price Volatility Vs. Market

How volatile is Mersana Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mersana Therapeutics undervalued compared to its fair value and its price relative to the market?

5.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MRSN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MRSN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MRSN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MRSN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRSN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRSN is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Mersana Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-8.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRSN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRSN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRSN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRSN's revenue (84.4% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: MRSN's revenue (84.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRSN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Mersana Therapeutics performed over the past 5 years?

-26.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRSN is currently unprofitable.

Growing Profit Margin: MRSN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MRSN is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.

Accelerating Growth: Unable to compare MRSN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MRSN has a negative Return on Equity (-25.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mersana Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: MRSN's short term assets ($294.9M) exceed its short term liabilities ($22.4M).

Long Term Liabilities: MRSN's short term assets ($294.9M) exceed its long term liabilities ($14.5M).


Debt to Equity History and Analysis

Debt Level: MRSN's debt to equity ratio (1.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MRSN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MRSN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MRSN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 42.5% each year


Next Steps

Dividend

What is Mersana Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRSN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRSN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRSN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Anna Protopapas (56 yo)

5.5yrs

Tenure

US$1,739,795

Compensation

Ms. Anna Protopapas has been the Chief Executive Officer and President of Mersana Therapeutics, Inc. since March 2015. Ms. Protopapas has extensive strategic leadership experience and a demonstrated track ...


CEO Compensation Analysis

Compensation vs Market: Anna's total compensation ($USD1.74M) is below average for companies of similar size in the US market ($USD4.57M).

Compensation vs Earnings: Anna's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Anna Protopapas
President5.5yrsUS$1.74m0.31%
$ 4.6m
Brian DeSchuytner
Senior Vice President of Finance & Product Strategy1.17yrsUS$1.09m0%
$ 0
Dirk Huebner
Chief Medical Officer1.83yrsUS$1.15m0%
$ 0
Mikhail Papisov
Co-Founderno datano datano data
Ashish Mandelia
VP, Controller & Principal Accounting Officer1yrno datano data
Timothy Lowinger
Chief Science & Technology Officer1.67yrsUS$1.05m0.018%
$ 273.8k
Sarah Carmody
Executive Director of Investor Relations & Corporate Communications1.83yrsno datano data
Radha Iyengar
Vice President of Legal Operationsno datano datano data
Eva Jack
Chief Business Officer & Company Secretary6.83yrsno datano data
Michael Kaufman
Chief Manufacturing Officer4.58yrsno datano data
Chuck Miller
Senior Vice President of Regulatory Affairs0.083yrno datano data

1.8yrs

Average Tenure

56yo

Average Age

Experienced Management: MRSN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Anna Protopapas
President5.5yrsUS$1.74m0.31%
$ 4.6m
David Mott
Independent Chairman8.17yrsUS$149.24k0.79%
$ 12.0m
Lawrence Alleva
Independent Director3yrsUS$126.57k0.0016%
$ 24.0k
Willard Dere
Independent Director2.5yrsUS$123.07k0%
$ 0
Kristen Hege
Independent Director4.08yrsUS$110.62k0%
$ 0
Andrew A. Hack
Independent Director3.67yrsUS$118.12k0%
$ 0
Misti Ushio
Board Observerno datano datano data
Martin Huber
Independent Director0.42yrno datano data

3.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: MRSN's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MRSN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.1%.


Top Shareholders

Company Information

Mersana Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mersana Therapeutics, Inc.
  • Ticker: MRSN
  • Exchange: NasdaqGS
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.509b
  • Shares outstanding: 68.42m
  • Website: https://www.mersana.com

Number of Employees


Location

  • Mersana Therapeutics, Inc.
  • 840 Memorial Drive
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRSNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2017
0M4DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2017

Biography

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:04
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.